Setterwalls advised Immunovia in connection with a rights issue of units

Setterwalls has advised Immunovia AB (publ), listed on Nasdaq Stockholm, in connection with a rights issue of units.

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate that a high-risk individual has developed pancreatic cancer.

Through the rights issue, Immunovia receives initial issue proceeds of approximately SEK 63.2 million before issue costs.